Where is Novartis AG (NVS) Headed?
Novartis AG (NYSE:NVS) is one of the best immunotherapy stocks to buy according to hedge funds.
Novartis A G (NVS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 7,465,850 | $1,029,316,861 | +4% | 0.35% |
| 2. | GQG Partners Rajiv Jain | 3,158,122 | $435,413,703 | +40% | 0.72% |
| 3. | Renaissance Technologies Jim Simons | 1,343,033 | $185,163,960 | -29% | 0.29% |
| 4. | 862,800 | $118,954,236 | +566% | 0.22% | |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 787,977 | $108,638,389 | 0.06% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,014,641 | $1,242,848,555 | 0.67% | |
| 2. | 8,876,906 | $1,223,859,537 | 0.07% | |
| 3. | 8,524,394 | $1,175,311,652 | 0.25% | |
| 4. | 7,579,274 | $1,044,954,508 | 0.79% | |
| 5. | 5,534,215 | $763,002,209 | 0.92% |
News See All
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript
Operator: Good morning and good afternoon, and welcome to the Novartis Q4 Full Year 2025 Results Release Conference Call and Live Webcast. [Operator Instructions] The conference is being recorded.
Why Analysts Are Closely Watching Novartis AG (NVS)
Novartis AG (NYSE:NVS) is among the most profitable healthcare stocks to buy.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug
Pharmaceutical firm Novartis AG (NYSE:NVS)’s shares are up by 44% over the past year and by 7.6% year-to-date. The tail end of 2025 saw several analysts discuss the firm.
14 Stocks on Jim Cramer's Radar
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed OpenAI's ChatGPT and business applications.
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub
TheFly reported on January 6 that Barclays upgraded NVS to Equal Weight from Underweight with a CHF 120 price target after a coverage transfer.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
Novartis AG (NYSE:NVS) is one of the most profitable NYSE stocks to buy right now.
Hedge Fund Resource Center Billionaire Hedge Funds
